StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
600165.SS$3.04+0.33%
Fair $3.04+0.0%

600165.SS

Ningxia Zhongke Biotechnology Co., Ltd

Basic Materials / Specialty ChemicalsShanghai

$3.04

+0.01 (+0.33%)

Fairly Valued+0.0%Fair Value $3.04Fund rank 26/100 · Data gapFallback financials|
SA 15/F
F-Score: 4/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 19%

FCF escenarios

weak_data · normalized FCF $-91.4M · quality 47.7/100

Data gap 26/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 12/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

15/100

F

Piotroski

4/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific commodity mid-cycle model required: targets are disabled until normalized cycle price/cost-curve/reserve data exists. ROE is -7.5%, below the 5% threshold
Thesis & Journal · 600165.SSLocal privado en este navegador · Ningxia Zhongke Biotechnology Co., Ltd
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$4.9B

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-7.5%

↓

Gross Margin

-20.0%

↓

Debt/Equity

0.01

↓
52-Week Range$3
$3$5

TradingView lightweight chart

600165.SS price, volumen y niveles de valoración

Último $3.040Periodo -5.8%
Fair value: $3.040

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-9.7%

FCF CAGR

—

FCF margin

-145.0%

FCF / Net income

7.13x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $444.5M · net income $-90.4M · FCF $-644.6M

2022-FY → 2025-FY

Gross margin

-20.0%-20.0% pts

Operating margin

-45.4%-23.8% pts

Net margin

-20.3%+14.6% pts

FCF margin

-145.0%-129.7% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$444.5M$444.5M$345.3M$285.7M$604.5M
Net Income$-90.4M$-90.4M$-538.9M$-464.7M$-211.0M
EBITDA$-2.7M$-2.7M$-306.3M$-235.2M$-28.3M
EPS-0.06-0.06-0.79-0.68-0.31
Gross Margin-20.0%-20.0%-19.5%-34.6%0.1%
Operating Margin-45.4%-45.4%-42.7%-58.4%-21.6%
Net Margin-20.3%-20.3%-156.1%-162.7%-34.9%
Balance Sheet
Debt/Equity0.010.013.209.931.76
Current Ratio2.712.71———
Cash Flow
Free Cash Flow$-644.6M$-644.6M$-91.4M$-34.5M$-92.7M
Returns
ROE-7.5%-7.5%-750.6%-468.7%-37.7%
Valuation
P/B4.064.0622.8922.858.33
Growth & Yield
Revenue Growth28.7%28.7%20.9%-52.7%—
EPS Growth92.9%92.9%-15.9%-120.5%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -40.7%

Total return

-40.7%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.79 → -0.06

Residual

-40.7%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-40.7%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.